FLT3 and acute myeloid leukemia: In FLT3-mutated R/R AML, VEN plus gilteritinib has shown an impressive complete response (CR) rate of 75% and a median OS of 10 months, even in patients previously treated with FLT3 inhibitors [100], and the “triplet” of AZA/VEN and gilteritinib showed high complete remission rates and deep molecular responses in newly diagnosed FLT3-mutated AML (Table 2) with manageable myelosuppression [101].